| [1] |
Yang XB, Zhang LH, Xue JN, et al. High incidence combination of multiple primary malignant tumors of the digestive system[J]. World J Gastroenterol, 2022, 28(41): 5982-5992. DOI: 10.3748/wjg.v28.i41.5982.
|
| [2] |
Parra-Medina R, Rocha F, Castañeda-González JP, et al. Synchronous or collision solid neoplasms and lymphomas: a systematic review of 308 case reports[J]. Medicine (Baltimore), 2022, 101(28): e28988. DOI: 10.1097/MD.0000000000028988.
|
| [3] |
Zhu CL, Peng LZ. Clinical analysis of multiple primary gastrointestinal malignant tumors: a 10-year case review of a single-center[J]. World J Gastrointest Oncol, 2024, 16(4): 1204-1212. DOI: 10.4251/wjgo.v16.i4.1204.
|
| [4] |
Marano L. Dual primary gastric and colorectal cancer: a complex challenge in surgical oncology[J]. World J Gastrointest Oncol, 2023, 15(12): 2049-2052. DOI: 10.4251/wjgo.v15.i12.2049.
|
| [5] |
Kobayashi K, Furukawa K, Ishikawa E, et al. Collision tumors of gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma[J]. Intern Med, 2021, 60(15): 2419-2424. DOI: 10.2169/internalmedicine.6124-20.
|
| [6] |
雷奇, 周爱萍, 杜春霞. 胃癌合并多原发癌的临床特征与治疗的研究进展[J]. 中国肿瘤生物治疗杂志, 2021, 28(4): 410-415. DOI: 10.3872/j.issn.1007-385x.2021.04.015.
|
| [7] |
Xue HM, Yang XM, Shen Q, et al. Gastric cancer causing schnitzler's metastasis: case report and systematic review of the features[J]. Acta Oncol, 2025, 64: 312-318. DOI: 10.2340/1651-226X.2025.41296.
pmid: 40008907
|
| [8] |
Phuong VT, Lieu DQ, Hanh BTM, et al. Synchronous occurrence of gastric adenocarcinoma and MALT-type lymphoma: a case report and literature review[J]. Radiol Case Rep, 2023, 18(8): 2730-2734. DOI: 10.1016/j.radcr.2023.05.035.
|
| [9] |
Zhu ML, Bai XQ, Liu XY. Gastric adenocarcinoma combined with mucosa-associated lymphoma[J]. Asian J Surg, 2024, 47(2): 1236-1238. DOI: 10.1016/j.asjsur.2023.11.045.
|
| [10] |
Lin YJ, Chen HX, Zhang FX, et al. Features of synchronous and metachronous dual primary gastric and colorectal cancer[J]. World J Gastrointest Oncol, 2023, 15(11): 1864-1873. DOI: 10.4251/wjgo.v15.i11.1864.
|
| [11] |
Kim HJ, Kim N, Choi YJ, et al. Clinicopathologic features of gastric cancer with synchronous and metachronous colorectal cancer in Korea: are microsatellite instability and p53 overexpression useful markers for predicting colorectal cancer in gastric cancer patients?[J]. Gastric Cancer, 2016, 19(3): 798-807. DOI: 10.1007/s10120-015-0552-6.
pmid: 26445944
|
| [12] |
Jia YF, Chen FF, Yang L, et al. Early gastric composite tumor comprising signet-ring cell carcinoma and mucosa-associated lymphoid tissue lymphoma: a case report[J]. World J Gastroenterol, 2024, 30(38): 4232-4238. DOI: 10.3748/wjg.v30.i38.4232.
|
| [13] |
陈正卓, 张荣辉, 罗斌, 等. 胃腺癌肠道转移16例临床病理学特征及误诊分析[J]. 中华转移性肿瘤杂志, 2025, 8(2): 209-214. DOI: 10.3760/cma.j.cn101548-20240624-00108.
|
| [14] |
Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2025, 23(5): 169-191. DOI: 10.6004/JNCCN.2025.0022.
|
| [15] |
Li YG, Han CC, Tang JQ. Efficacy and safety of neoadjuvant therapy combined with immunotherapy in MMR‑proficient/microsatellite stable non‑metastatic rectal cancer: a systematic review and meta‑ analysis[J]. J Cancer Res Clin Oncol, 2025, 152(1): 9. DOI: 10.1007/s00432-025-06387-4.
|
| [16] |
Lago ADM, Moga MA, Hogea M, et al. Therapeutic advances in rectal cancer[J]. Am J Ther, 2025, 32(5): e451-e457. DOI: 10.1097/MJT.0000000000002015.
pmid: 41099737
|
| [17] |
Sexton RE, Al Hallak MN, Diab M, et al. Gastric cancer: a comprehensive review of current and future treatment strategies[J]. Cancer Metastasis Rev, 2020, 39(4): 1179-1203. DOI: 10.1007/s10555-020-09925-3.
|
| [18] |
Antoniotti C, Rossini D, Pietrantonio F, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial[J]. Lancet Oncol, 2022, 23(7): 876-887. DOI: 10.1016/S1470-2045(22)00274-1.
|
| [19] |
Xu RH, Wang F, Wang ZX, et al. Updated efficacy and subgroup analysis of first-line serplulimab plus bevacizumab and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: a phase 2/3 study[J]. J Clin Oncol, 2025, 43(4_suppl): 170. DOI: 10.1200/JCO.2025.43.4_suppl.170.
|
